UNLABELLED: Cutaneous melanoma is often characterized by the presence of tumor-infiltrating lymphocytes (TILs). The degree of such infiltration and cell activation are considered significant prognostic factors reflecting the host's immune response to the tumor; thus, patients with peritumoral infiltration may have a better prognosis and may also achieve a better response to interleukin-2 (IL2) immunotherapy. There is evidence that the expression of cluster designation (CD) 25 antigen (IL2 receptor [IL2R]) is a good marker of activity of T lymphocytes against melanoma cells. The aim of this study was to evaluate in vivo the binding of 99mTc-IL2 to lymphocytes infiltrating cutaneous melanoma and to determine whether such uptake correlates with immunologic and histologic data, thus providing useful prognostic information for IL2 therapy in patients with advanced disease. METHODS: Thirty patients with cutaneous lesions suspected of being melanoma were studied. Planar gamma-camera images over known tumor sites were acquired 1 h after the injection of 111-185 MBq of 99mTc-IL2. Tumor uptake of 99mTc-IL2 was measured as a target-to-background (T/B) radioactivity ratio. All patients underwent surgery, and histologic evaluation of the resected lesion was performed. The percentage of different peripheral blood lymphocyte subsets (CD3, CD4, CD8, CD16, CD25) and the percentage of IL2R-positive tumor cells on histologic sections were also measured. RESULTS: At final histology, 21 lesions were found to be melanoma and 9 were classified as benign. In 15 of 21 (71%) melanomas and 2 of 9 (22%) benign cutaneous lesions, we found uptake of 99mTc-IL2. The calculated T/B ratios correlated significantly with the number of IL2R-positive TILs. CONCLUSION: 99mTc-IL2 scintigraphy provides a means of in vivo measurement of the extent of tumor infiltration of IL2R-positive cells, thereby providing valuable prognostic information for selection of patients who may benefit from IL2 immunotherapy.
UNLABELLED: Cutaneous melanoma is often characterized by the presence of tumor-infiltrating lymphocytes (TILs). The degree of such infiltration and cell activation are considered significant prognostic factors reflecting the host's immune response to the tumor; thus, patients with peritumoral infiltration may have a better prognosis and may also achieve a better response to interleukin-2 (IL2) immunotherapy. There is evidence that the expression of cluster designation (CD) 25 antigen (IL2 receptor [IL2R]) is a good marker of activity of T lymphocytes against melanoma cells. The aim of this study was to evaluate in vivo the binding of 99mTc-IL2 to lymphocytes infiltrating cutaneous melanoma and to determine whether such uptake correlates with immunologic and histologic data, thus providing useful prognostic information for IL2 therapy in patients with advanced disease. METHODS: Thirty patients with cutaneous lesions suspected of being melanoma were studied. Planar gamma-camera images over known tumor sites were acquired 1 h after the injection of 111-185 MBq of 99mTc-IL2. Tumor uptake of 99mTc-IL2 was measured as a target-to-background (T/B) radioactivity ratio. All patients underwent surgery, and histologic evaluation of the resected lesion was performed. The percentage of different peripheral blood lymphocyte subsets (CD3, CD4, CD8, CD16, CD25) and the percentage of IL2R-positive tumor cells on histologic sections were also measured. RESULTS: At final histology, 21 lesions were found to be melanoma and 9 were classified as benign. In 15 of 21 (71%) melanomas and 2 of 9 (22%) benign cutaneous lesions, we found uptake of 99mTc-IL2. The calculated T/B ratios correlated significantly with the number of IL2R-positive TILs. CONCLUSION: 99mTc-IL2 scintigraphy provides a means of in vivo measurement of the extent of tumor infiltration of IL2R-positive cells, thereby providing valuable prognostic information for selection of patients who may benefit from IL2 immunotherapy.
Authors: Alessio Annovazzi; Calogero D'Alessandria; Elena Bonanno; Stephen J Mather; Bart Cornelissen; Christophe van de Wiele; Rudi A Dierckx; Maurizio Mattei; Graziana Palmieri; Francesco Scopinaro; Alberto Signore Journal: Eur J Nucl Med Mol Imaging Date: 2006-01-27 Impact factor: 9.236
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: David Loose; Alberto Signore; Ludovicus Staelens; Katia Vanden Bulcke; Hubert Vermeersch; Rudi Andre Dierckx; Elena Bonanno; Christophe Van de Wiele Journal: Eur J Nucl Med Mol Imaging Date: 2007-10-10 Impact factor: 9.236
Authors: Andor W J M Glaudemans; Elena Bonanno; Filippo Galli; Clark J Zeebregts; Erik F J de Vries; Michel Koole; Gert Luurtsema; Hendrikus H Boersma; Maurizio Taurino; Riemer H J A Slart; Alberto Signore Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-16 Impact factor: 9.236
Authors: Erik H J G Aarntzen; Mangala Srinivas; Caius G Radu; Cornelis J A Punt; Otto C Boerman; Carl G Figdor; Wim J G Oyen; I Jolanda M de Vries Journal: Cell Mol Life Sci Date: 2012-10-05 Impact factor: 9.261
Authors: Calogero D'Alessandria; Valentina di Gialleonardo; Marco Chianelli; Stephen J Mather; Erik F J de Vries; Francesco Scopinaro; Rudi A Dierck; Alberto Signore Journal: Mol Imaging Biol Date: 2009-12-01 Impact factor: 3.488
Authors: Elly L van der Veen; Frans V Suurs; Frederik Cleeren; Guy Bormans; Philip H Elsinga; Geke A P Hospers; Marjolijn N Lub-de Hooge; Elisabeth G E de Vries; Erik F J de Vries; Inês F Antunes Journal: J Nucl Med Date: 2020-02-28 Impact factor: 11.082